PTC Therapeutics, Inc. (PTCT)
71.02
+1.20
(+1.72%)
USD |
NASDAQ |
Aug 24, 16:00
71.02
0.00 (0.00%)
After-Hours: 20:00
PTC Therapeutics Enterprise Value : 4.285B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 4.285B |
| August 20, 2026 | 4.344B |
| August 19, 2026 | 4.606B |
| August 18, 2026 | 4.519B |
| August 17, 2026 | 4.540B |
| August 14, 2026 | 4.442B |
| August 13, 2026 | 4.464B |
| August 12, 2026 | 4.520B |
| August 11, 2026 | 4.609B |
| August 10, 2026 | 4.686B |
| August 07, 2026 | 4.576B |
| August 06, 2026 | 4.371B |
| August 05, 2026 | 4.234B |
| August 04, 2026 | 4.225B |
| August 03, 2026 | 4.143B |
| July 31, 2026 | 4.134B |
| July 30, 2026 | 4.760B |
| July 29, 2026 | 4.674B |
| July 28, 2026 | 4.749B |
| July 27, 2026 | 4.784B |
| July 24, 2026 | 4.869B |
| July 23, 2026 | 5.004B |
| July 22, 2026 | 5.000B |
| July 21, 2026 | 5.009B |
| July 20, 2026 | 4.968B |
| Date | Value |
|---|---|
| July 17, 2026 | 5.016B |
| July 16, 2026 | 5.010B |
| July 15, 2026 | 5.037B |
| July 14, 2026 | 4.972B |
| July 13, 2026 | 5.244B |
| July 10, 2026 | 5.538B |
| July 09, 2026 | 5.929B |
| July 08, 2026 | 5.848B |
| July 07, 2026 | 5.900B |
| July 06, 2026 | 5.587B |
| July 02, 2026 | 5.409B |
| July 01, 2026 | 5.246B |
| June 30, 2026 | 5.264B |
| June 29, 2026 | 5.263B |
| June 26, 2026 | 5.500B |
| June 25, 2026 | 5.507B |
| June 24, 2026 | 5.499B |
| June 23, 2026 | 5.310B |
| June 22, 2026 | 5.213B |
| June 18, 2026 | 5.049B |
| June 17, 2026 | 5.011B |
| June 16, 2026 | 4.575B |
| June 15, 2026 | 4.865B |
| June 12, 2026 | 4.730B |
| June 11, 2026 | 4.695B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Insmed, Inc. | 27.04B |
| Madrigal Pharmaceuticals, Inc. | 11.44B |
| Protagonist Therapeutics, Inc. | 9.207B |
| Biogen, Inc. | 39.09B |
| BioMarin Pharmaceutical, Inc. | 16.25B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 83.50M |
| Revenue (Quarterly) | 360.52M |
| Total Expenses (Quarterly) | 277.02M |
| EPS Diluted (Quarterly) | 0.9178 |
| Gross Profit Margin (Quarterly) | 91.19% |
| Profit Margin (Quarterly) | 23.16% |
| Earnings Yield | -0.84% |
| Operating Earnings Yield | 1.92% |
| Normalized Earnings Yield | -0.9453 |